Dr. David M. Nanus

Dr. David M. Nanus, MD, is a prominent figure in genitourinary oncology and serves as Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine and NewYork-Presbyterian Hospital. He is also the Associate Director for Clinical Services at the Sandra and Edward Meyer Cancer Center and holds the Mark W. Pasmantier Professorship of Hematology and Oncology in Medicine. Dr. Nanus received his medical degree from Cornell University Medical College and completed his residency at NewYork-Presbyterian/Weill Cornell Medical Center, followed by a fellowship in medical oncology at Memorial Sloan Kettering Cancer Center. Board-certified in Internal Medicine and Medical Oncology, he provides comprehensive care for patients with prostate, bladder, kidney, and testicular cancers, offering both in-person and telehealth consultations.

Internationally recognized for his contributions to translational cancer research, Dr. Nanus focuses on understanding the molecular and genetic mechanisms of tumor progression and therapy resistance in genitourinary malignancies. His research integrates laboratory science with clinical applications, aiming to develop and test targeted therapies that improve outcomes for patients with advanced or refractory disease. He has authored more than 130 peer-reviewed publications and leads clinical trials that examine innovative treatment regimens, particularly for patients with hormone-resistant prostate cancer and metastatic urothelial tumors. His efforts have significantly advanced personalized approaches in oncology by linking tumor biology to therapeutic decision-making.

Beyond his clinical and research work, Dr. Nanus is a dedicated educator and institutional leader. He has mentored numerous fellows and junior investigators in oncology and plays an active role in shaping cancer care delivery at Weill Cornell and its affiliated hospitals. His leadership is instrumental in aligning research discoveries with patient care strategies and expanding access to state-of-the-art therapies. Through his continued impact in clinical care, academic mentorship, and translational research, Dr. Nanus remains a driving force in the advancement of genitourinary oncology.